Thirty percent of patients with severe hemophilia treated with factor fVIII (fVlll) develop anti-fVIII antibodies (inhibitors). This is the most significant complication in the management of patients with hemophilia A leading to significant increases In morbidity as well as cost of treatment. Antibodies to fVIII can also develop in patients with previously normal coagulation leading to acquired hemophilia. These antibodies that develop can inhibit the biological activity of fVIII and necessitate the use of bypassing agents for the treatment of bleeding episodes. However, for unknown reasons, some patients display poor hemostatic response to bypass therapy. Thus, improved treatment options are needed, especially for severe or life-threatening bleeding events. Some biological determinants have been identified that increase the risk of inhibitor development. However, little is known about how hemophilia genotype relates to the ultimate epitope spectrum of the B-cell response or how the epitope spectrum affects the response to treatment and immune tolerance. We have recently shown that epitope specificity and inhibitor kinetics within the C2 domain are more important than inhibitor titer in response to fVlll in acquired hemophilia plasma and a murine monoclonal antibody (MAb) system. The central hypothesis of this project is that the inhibitor epitope spectrum of an individual patient can be used to predict the response to infusions of fVIII with or without bypassing agents. We propose to define further the epitopes on fVIII using a large panel of non-overlapping antl-fVIII MAbs in multiple in vitro assays (Aim 1). Given known discrepancies between the different in vitro assays and bleeding phenotype we will study the importance of different epitopes on murine in vivo bleeding phenotypes and fibrin clot structure (Aim 2).
In Aim 3, we will adapt our novel ELISA-based epitope mapping protocol to a more robust microsphere-based assay and investigate in a cross-sectional study how polyclonal patient plasma epitope maps correlate with the response to fVIII and bypassing agents in vitro. Ultimately these results could provide a simple clinical test that may predict response to fVIII and bypassing agents in high titer acquired and congenital hemophilia patients.

Public Health Relevance

Inhibitor development is the most significant complication in the management of pafients with hemophilia A. These inhibitors block the biological activity of N and necessitate the use of bypassing agents for the treatment of bleeding episodes. This goal of this project is to increase our knowledge of different types inhibitors and to provide an assay that better predicts an individual patient's response to treatment

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54HL112309-01
Application #
8391968
Study Section
Special Emphasis Panel (ZHL1-CSR-C (F1))
Project Start
2012-05-01
Project End
2017-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
1
Fiscal Year
2012
Total Cost
$315,411
Indirect Cost
$110,383
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Brown, Harrison C; Zakas, Philip M; George, Stephan N et al. (2018) Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A. Mol Ther Methods Clin Dev 9:57-69
Zhang, Yun; Qiu, Yongzhi; Blanchard, Aaron T et al. (2018) Platelet integrins exhibit anisotropic mechanosensing and harness piconewton forces to mediate platelet aggregation. Proc Natl Acad Sci U S A 115:325-330
Healey, J F; Parker, E T; Lollar, P (2018) Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation. J Thromb Haemost 16:303-315
Batsuli, G; Ito, J; Mercer, R et al. (2018) Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model. J Thromb Haemost 16:1779-1788
Qiu, Yongzhi; Ahn, Byungwook; Sakurai, Yumiko et al. (2018) Microvasculature-on-a-chip for the long-term study of endothelial barrier dysfunction and microvascular obstruction in disease. Nat Biomed Eng 2:453-463
Sakurai, Yumiko; Hardy, Elaissa T; Ahn, Byungwook et al. (2018) A microengineered vascularized bleeding model that integrates the principal components of hemostasis. Nat Commun 9:509
Brockman, Joshua M; Blanchard, Aaron T; Pui-Yan Ma, Victor et al. (2018) Mapping the 3D orientation of piconewton integrin traction forces. Nat Methods 15:115-118
Qiu, Yongzhi; Tong, Sheng; Zhang, Linlin et al. (2017) Magnetic forces enable controlled drug delivery by disrupting endothelial cell-cell junctions. Nat Commun 8:15594
Deng, W; Wang, Y; Druzak, S A et al. (2017) A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor. J Thromb Haemost 15:1867-1877
Mannino, Robert G; Santiago-Miranda, Adriana N; Pradhan, Pallab et al. (2017) 3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitro. Lab Chip 17:407-414

Showing the most recent 10 out of 46 publications